H.R. 2375: Preserve Access to Affordable Generics and Biosimilars Act

CBO Score

$-544,000,000

Documentation

Date of Report

Wed May 8th, 2019

CBO Report Details

Legislation Details

116th Congress

To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.

Sponsor: Rep. Jerrold Nadler — D — NY

To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.

View the full vote history of this bill on GovTrack.us.

As a registered user, you receive personalized updates to your inbox or dashboard when elected officials vote to spend more of your money. Choose to receive updates daily, weekly, monthly, or as they happen.

JOIN US!

Sign up below to receive updates when your Members of Congress vote for new spending increases or cuts.

Lost your Password?

Don't be sad- we've got your back. Just enter your email below and instructions on resetting your password will be sent to you.

×
+ + HIGH LOW +
+ + HIGH LOW +